Evidence map›Paper›PMID 37176131›Full record

ArticleInternational journal of molecular sciences2023

Antiviral Activity of Zinc Oxide Nanoparticles against SARS-CoV-2.

Stella Wolfgruber, Julia Rieger, Olavo Cardozo, Benjamin Punz, Martin Himly, Andreas Stingl, Patricia M A Farias, Peter M Abuja, Kurt Zatloukal

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Navigating theNanoscale advances · 2026
    Review
  4. Review
  5. Metallo-herb complexes as emerging therapeutics: chemistry, synthesis approaches, and pharmacological insights.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Nanoparticles-Delivered Circular RNA Strategy as a Novel Antitumor Approach.International journal of molecular sciences · 2024
    Review
  15. RSC advances · 2024
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Stella WolfgruberDiagnostic and Research Center for Molecular Biomedicine, Institute of Pathology, Medical University of Graz, 8010 Graz, Austria.
Julia RiegerDiagnostic and Research Center for Molecular Biomedicine, Institute of Pathology, Medical University of Graz, 8010 Graz, Austria.
Olavo CardozoPHORNANO Holding GmbH, Kleinengersdorferstrasse 24, 2100 Korneuburg, Austria.
Benjamin PunzDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, 5020 Salzburg, Austria.ORCID 0000-0001-9662-4739
Martin HimlyDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, 5020 Salzburg, Austria.ORCID 0000-0001-5416-085X
Andreas StinglPHORNANO Holding GmbH, Kleinengersdorferstrasse 24, 2100 Korneuburg, Austria.
Patricia M A FariasPHORNANO Holding GmbH, Kleinengersdorferstrasse 24, 2100 Korneuburg, Austria.ORCID 0000-0001-8800-6500
Peter M AbujaDiagnostic and Research Center for Molecular Biomedicine, Institute of Pathology, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0003-1957-4066
Kurt ZatloukalDiagnostic and Research Center for Molecular Biomedicine, Institute of Pathology, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0001-5299-7218

Funding

Austrian Research Promotion Agency #888037
6 · The paper itself

Abstract

The highly contagious SARS-CoV-2 virus is primarily transmitted through respiratory droplets, aerosols, and contaminated surfaces. In addition to antiviral drugs, the decontamination of surfaces and personal protective equipment (PPE) is crucial to mitigate the spread of infection. Conventional approaches, including ultraviolet radiation, vaporized hydrogen peroxide, heat and liquid chemicals, can damage materials or lack comprehensive, effective disinfection. Consequently, alternative material-compatible and sustainable methods, such as nanomaterial coatings, are needed. Therefore, the antiviral activity of two novel zinc-oxide nanoparticles (ZnO-NP) against SARS-CoV-2 was investigated in vitro. Each nanoparticle was produced by applying highly efficient "green" synthesis techniques, which are free of fossil derivatives and use nitrate, chlorate and sulfonate salts as starting materials and whey as chelating agents. The two "green" nanomaterials differ in size distribution, with ZnO-NP-45 consisting of particles ranging from 30 nm to 60 nm and ZnO-NP-76 from 60 nm to 92 nm. Human lung epithelial cells (Calu-3) were infected with SARS-CoV-2, pre-treated in suspensions with increasing ZnO-NP concentrations up to 20 mg/mL. Both "green" materials were compared to commercially available ZnO-NP as a reference. While all three materials were active against both virus variants at concentrations of 10-20 mg/mL, ZnO-NP-45 was found to be more active than ZnO-NP-76 and the reference material, resulting in the inactivation of the Delta and Omicron SARS-CoV-2 variants by a factor of more than 10

Indexed as

COVID-19NanoparticlesZinc OxideAntiviral AgentsHumansProspective StudiesSARS-CoV-2Ultraviolet RaysAntiviral AgentsZinc OxideantiviralSARS-CoV-2zinc oxide nanoparticles

Identifiers

PMID37176131
PMCPMC10179150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.